Boundless Bio Files 10-Q, Details Financials
Ticker: BOLD · Form: 10-Q · Filed: Aug 12, 2024 · CIK: 1782303
| Field | Detail |
|---|---|
| Company | Boundless Bio, INC. (BOLD) |
| Form Type | 10-Q |
| Filed Date | Aug 12, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Boundless Bio 10-Q filed: Q2 2024 financials out, convertible stock and incentive plans detailed.
AI Summary
Boundless Bio, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial status, including details on its convertible preferred stock and incentive plans. Key personnel mentioned include Chris Hassig and Neil Abdollahian. The filing also references the company's fiscal year end of December 31.
Why It Matters
This filing provides investors with an update on Boundless Bio's financial health and operational details for the second quarter of 2024.
Risk Assessment
Risk Level: medium — As a 10-Q filing, it contains detailed financial information which can be complex and subject to interpretation, impacting investment decisions.
Key Numbers
- 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial data is reported.)
- 20240812 — Filing Date (Shows when the 10-Q was officially submitted to the SEC.)
- 001-41989 — SEC File Number (Unique identifier for Boundless Bio's filings with the SEC.)
Key Players & Entities
- Boundless Bio, Inc. (company) — Filer of the 10-Q
- June 30, 2024 (date) — End of reporting period
- Chris Hassig (person) — Mentioned in relation to incentive plan
- Neil Abdollahian (person) — Mentioned in filing
- December 31 (date) — Fiscal year end
FAQ
What is the total cash and cash equivalents reported as of December 31, 2023?
The filing references 'us-gaap:CashEquivalentsMember' for '2023-12-31', indicating cash and equivalents were reported on this date, though the specific dollar amount is not provided in this snippet.
What is the fiscal year end for Boundless Bio, Inc.?
The fiscal year end for Boundless Bio, Inc. is December 31.
Who are the key individuals mentioned in relation to the company's incentive plans?
Chris Hassig is mentioned in relation to the 'TwoThousandTwentyFourIncentivePlanMember'.
What type of preferred stock is mentioned in the filing?
The filing mentions 'us-gaap:ConvertiblePreferredStockMember' and 'bold:SeriesAConvertiblePreferredStockMember'.
What is the SIC code for Boundless Bio, Inc.?
The Standard Industrial Classification (SIC) code for Boundless Bio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,494 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2024-08-12 16:10:21
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share BOLD Nasdaq Global Select
Filing Documents
- bold-20240630.htm (10-Q) — 1571KB
- bold-ex10_1.htm (EX-10.1) — 33KB
- bold-ex31_1.htm (EX-31.1) — 14KB
- bold-ex31_2.htm (EX-31.2) — 14KB
- bold-ex32_1.htm (EX-32.1) — 13KB
- 0000950170-24-095421.txt ( ) — 6427KB
- bold-20240630.xsd (EX-101.SCH) — 875KB
- bold-20240630_htm.xml (XML) — 1079KB
Financial Statements (Unaudited)
Financial Statements (Unaudited) 1 Condensed Balance Sheets 1 Condensed Statements of Operations and Comprehensive Loss 2 Condensed Statements of Convertible Preferred Stock and Stockholders' Equity / (Deficit ) 3 Condensed Statements of Cash Flows 4 Notes to Condensed Financial Statements 5 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 23 Item 4.
Controls and Procedures
Controls and Procedures 23 PART II. OTHER INFORMATION 25 Item 1.
Legal Proceedings
Legal Proceedings 25 Item 1A.
Risk Factors
Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosures 25 Item 5. Other Information 25 Item 6. Exhibits 27
—FINANCIAL INFORMATION
PART I—FINANCIAL INFORMATION Ite m 1. Financial Statements. Boundless Bio, Inc. Condensed Bal ance Sheets (in thousands, except share and par value data) June 30, 2024 December 31, 2023 (unaudited) Assets Current assets Cash and cash equivalents $ 31,363 $ 23,706 Short-term investments 147,927 97,046 Prepaid expenses and other current assets 3,842 3,452 Total current assets 183,132 124,204 Property and equipment, net 3,739 2,573 Right-of-use asset, net 754 2,002 Restricted cash 560 560 Other assets 18 555 Total assets $ 188,203 $ 129,894 Liabilities, convertible preferred stock, and stockholders' equity / (deficit) Current liabilities Accounts payable and accrued liabilities $ 6,066 $ 4,266 Accrued compensation 2,054 2,898 Lease liabilities, current portion 837 2,195 Total current liabilities 8,957 9,359 Commitments and contingencies (Note 8) Convertible preferred stock, $ 0.0001 par value; no shares authorized, issued, or outstanding as of June 30, 2024; 287,446,844 shares authorized, issued, and outstanding as of December 31, 2023; liquidation preference of $ 252.1 million as of December 31, 2023 — 247,617 Stockholders' equity / (deficit): Preferred stock, $ 0.0001 par value; 70,000,000 shares authorized and no shares issued and outstanding as of June 30, 2024; no shares authorized and no shares issued and outstanding as of December 31, 2023 — — Common stock, $ 0.0001 par value; 700,000,000 shares authorized, 22,254,537 shares issued, and 22,254,102 shares outstanding as of June 30, 2024; 402,600,000 shares authorized, 1,248,493 shares issued, and 1,247,012 shares outstanding as of December 31, 2023 2 — Additional paid-in-capital 347,823 8,987 Accumulated other comprehensive income / (loss) ( 64 ) 40 Accumulated deficit ( 168,515 ) ( 136,109 ) Total stockholders' equity / (deficit) 179,246 ( 127,082 )